Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study

Objective In Guatemala, cirrhosis is among the 10 leading causes of death, and mortality rates have increased lately. The reasons for this heavy burden of disease are not clear as the prevalence of prominent risk factors, such as hepatitis B virus, hepatitis C virus and heavy alcohol consumption, ap...

Full description

Bibliographic Details
Main Authors: Neal D Freedman, Barry I Graubard, Christian S Alvarez, Michael Dean, Alvaro Rivera-Andrade, Eliseo Guallar, Elisa Hernández, Kira Escobar, Carmen I Villagrán, María F Kroker-Lobos, Joshua W Smith, Patricia A Egner, Mariana Lazo, John D Groopman, Manuel Ramírez-Zea, Katherine A McGlynn
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/7/1/e000380.full
id doaj-dd1f515862c54d4abd9dfbe019873482
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Neal D Freedman
Barry I Graubard
Christian S Alvarez
Michael Dean
Alvaro Rivera-Andrade
Eliseo Guallar
Elisa Hernández
Kira Escobar
Carmen I Villagrán
María F Kroker-Lobos
Joshua W Smith
Patricia A Egner
Mariana Lazo
John D Groopman
Manuel Ramírez-Zea
Katherine A McGlynn
spellingShingle Neal D Freedman
Barry I Graubard
Christian S Alvarez
Michael Dean
Alvaro Rivera-Andrade
Eliseo Guallar
Elisa Hernández
Kira Escobar
Carmen I Villagrán
María F Kroker-Lobos
Joshua W Smith
Patricia A Egner
Mariana Lazo
John D Groopman
Manuel Ramírez-Zea
Katherine A McGlynn
Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
BMJ Open Gastroenterology
author_facet Neal D Freedman
Barry I Graubard
Christian S Alvarez
Michael Dean
Alvaro Rivera-Andrade
Eliseo Guallar
Elisa Hernández
Kira Escobar
Carmen I Villagrán
María F Kroker-Lobos
Joshua W Smith
Patricia A Egner
Mariana Lazo
John D Groopman
Manuel Ramírez-Zea
Katherine A McGlynn
author_sort Neal D Freedman
title Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
title_short Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
title_full Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
title_fullStr Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
title_full_unstemmed Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control study
title_sort aflatoxin b1 exposure and liver cirrhosis in guatemala: a case–control study
publisher BMJ Publishing Group
series BMJ Open Gastroenterology
issn 2054-4774
publishDate 2020-11-01
description Objective In Guatemala, cirrhosis is among the 10 leading causes of death, and mortality rates have increased lately. The reasons for this heavy burden of disease are not clear as the prevalence of prominent risk factors, such as hepatitis B virus, hepatitis C virus and heavy alcohol consumption, appears to be low. Aflatoxin B1 (AFB1) exposure, however, appears to be high, and thus could be associated with the high burden of cirrhosis. Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, is not clear.Design Cirrhosis cases (n=100) from two major referral hospitals in Guatemala City were compared with controls (n=200) from a cross-sectional study. Logistic regression was used to estimate the ORs and 95% CIs of cirrhosis and quintiles of AFB1 in crude and adjusted models. A sex-stratified analysis was also conducted.Results The median AFB1 level was significantly higher among the cases (11.4 pg/mg) than controls (5.11 pg/mg). In logistic regression analyses, higher levels of AFB1 was associated with cirrhosis (quintile 5 vs quintile 1, OR: 11.55; 95% CI 4.05 to 32.89). No attenuation was observed with adjustment by sex, ethnicity, hepatitis B virus status, and heavy alcohol consumption. A significantly increasing trend in association was observed in both models (p trend <0.01). Additionally, the cirrhosis–AFB1 association was more prominent among men.Conclusions The current study found a significant positive association between AFB1 exposure and cirrhosis. Mitigation of AFB1 exposure and a better understanding of additional risk factors may be important to reduce the burden of cirrhosis in Guatemala.
url https://bmjopengastro.bmj.com/content/7/1/e000380.full
work_keys_str_mv AT nealdfreedman aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT barryigraubard aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT christiansalvarez aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT michaeldean aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT alvaroriveraandrade aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT eliseoguallar aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT elisahernandez aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT kiraescobar aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT carmenivillagran aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT mariafkrokerlobos aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT joshuawsmith aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT patriciaaegner aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT marianalazo aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT johndgroopman aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT manuelramirezzea aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
AT katherineamcglynn aflatoxinb1exposureandlivercirrhosisinguatemalaacasecontrolstudy
_version_ 1724328489669099520
spelling doaj-dd1f515862c54d4abd9dfbe0198734822021-01-22T06:30:19ZengBMJ Publishing GroupBMJ Open Gastroenterology2054-47742020-11-017110.1136/bmjgast-2020-000380Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case–control studyNeal D Freedman0Barry I Graubard1Christian S Alvarez2Michael Dean3Alvaro Rivera-Andrade4Eliseo Guallar5Elisa Hernández6Kira Escobar7Carmen I Villagrán8María F Kroker-Lobos9Joshua W Smith10Patricia A Egner11Mariana Lazo12John D Groopman13Manuel Ramírez-Zea14Katherine A McGlynn151 Division of Cancer Epidemiology and Genetics, NIH, DHHS, National Cancer Institute, Rockville, Maryland, USA Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USADivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USADivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USAINCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala, GuatemalaDepartments of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, USACentro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala, GuatemalaCentro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala, GuatemalaCentro de Investigaciones Biomédicas, Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala, Guatemala, GuatemalaINCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala, GuatemalaDepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USADepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USADepartment of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USADepartment of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USAINCAP Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala, GuatemalaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USAObjective In Guatemala, cirrhosis is among the 10 leading causes of death, and mortality rates have increased lately. The reasons for this heavy burden of disease are not clear as the prevalence of prominent risk factors, such as hepatitis B virus, hepatitis C virus and heavy alcohol consumption, appears to be low. Aflatoxin B1 (AFB1) exposure, however, appears to be high, and thus could be associated with the high burden of cirrhosis. Whether AFB1 increases the risk of cirrhosis in the absence of viral infection, however, is not clear.Design Cirrhosis cases (n=100) from two major referral hospitals in Guatemala City were compared with controls (n=200) from a cross-sectional study. Logistic regression was used to estimate the ORs and 95% CIs of cirrhosis and quintiles of AFB1 in crude and adjusted models. A sex-stratified analysis was also conducted.Results The median AFB1 level was significantly higher among the cases (11.4 pg/mg) than controls (5.11 pg/mg). In logistic regression analyses, higher levels of AFB1 was associated with cirrhosis (quintile 5 vs quintile 1, OR: 11.55; 95% CI 4.05 to 32.89). No attenuation was observed with adjustment by sex, ethnicity, hepatitis B virus status, and heavy alcohol consumption. A significantly increasing trend in association was observed in both models (p trend <0.01). Additionally, the cirrhosis–AFB1 association was more prominent among men.Conclusions The current study found a significant positive association between AFB1 exposure and cirrhosis. Mitigation of AFB1 exposure and a better understanding of additional risk factors may be important to reduce the burden of cirrhosis in Guatemala.https://bmjopengastro.bmj.com/content/7/1/e000380.full